Knight Therapeutics Secures New Drug Approval in Brazil
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INCY?
Source: Globenewswire
- New Indication Approved: Knight Therapeutics' Brazilian affiliate, United Medical Ltda., received ANVISA approval for MINJUVI® in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, marking a significant expansion in treatment options that is expected to greatly improve patient outcomes.
- Clinical Data Support: The approval is backed by clinical study data demonstrating meaningful response rates and durable disease control with MINJUVI® combined with R2, which is anticipated to enhance Knight's competitiveness in the Latin American market and meet the growing treatment demand.
- Strengthened Strategic Partnership: Knight entered into an exclusive supply and distribution agreement with Incyte in 2021, further solidifying its position in the Latin American market, with expectations that the promotion of MINJUVI® will increase market share and enhance the company's influence in oncology treatment.
- Positive Future Outlook: This approval not only provides Brazilian patients with a new treatment option but also showcases Knight's strong capabilities in rapid approval processes, which is expected to drive business growth in Latin America and further fulfill its commitment to high-quality cancer care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 92.540
Low
73.00
Averages
100.31
High
125.00
Current: 92.540
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Knight Therapeutics Submits MINJUVI Supplemental Application for New Indication
- New Indication Application: Knight Therapeutics' Argentine and Mexican affiliates have submitted a supplemental application for MINJUVI® (tafasitamab) to local regulatory agencies, aiming to expand the product's applicability in the Latin American market and enhance its competitive edge.
- Market Expansion Strategy: Since signing an exclusive supply agreement with Incyte in 2021, Knight has launched MINJUVI® in Brazil, Mexico, and Argentina, planning to leverage the new indication approval to meet diverse patient needs, thereby increasing sales potential and market share.
- Clinical Data Support: In a Phase 3 clinical trial for relapsed follicular lymphoma, MINJUVI® demonstrated a significant improvement in progression-free survival, reaching 22.37 months, indicating the drug's efficacy in treatment, which may attract more physician interest.
- Future Development Outlook: Knight Therapeutics CEO Samira Sakhia emphasized that MINJUVI® represents multiple therapies rather than a single product, and with the launch of new indications, the company will continue to focus on improving patient health and driving long-term growth in the Latin American market.
See More
Knight Therapeutics Secures New Drug Approval in Brazil
- New Indication Approved: Knight Therapeutics' Brazilian affiliate, United Medical Ltda., received ANVISA approval for MINJUVI® in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, marking a significant expansion in treatment options that is expected to greatly improve patient outcomes.
- Clinical Data Support: The approval is backed by clinical study data demonstrating meaningful response rates and durable disease control with MINJUVI® combined with R2, which is anticipated to enhance Knight's competitiveness in the Latin American market and meet the growing treatment demand.
- Strengthened Strategic Partnership: Knight entered into an exclusive supply and distribution agreement with Incyte in 2021, further solidifying its position in the Latin American market, with expectations that the promotion of MINJUVI® will increase market share and enhance the company's influence in oncology treatment.
- Positive Future Outlook: This approval not only provides Brazilian patients with a new treatment option but also showcases Knight's strong capabilities in rapid approval processes, which is expected to drive business growth in Latin America and further fulfill its commitment to high-quality cancer care.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
Incyte Receives EU Approval for Zynyz in New Indication
- New Indication Approval: Incyte announced that its drug Zynyz (retifanlimab) in combination with carboplatin and paclitaxel has received approval from the European Commission for the treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC), marking the second indication for the drug in Europe.
- Clinical Trial Support: This approval is supported by data from the Phase 3 POD1UM-303/InterAACT2 trial, which evaluated the efficacy of Zynyz versus placebo in combination with carboplatin and paclitaxel, demonstrating significant effectiveness in adult patients who had not previously received systemic chemotherapy.
- Market Potential Expansion: Zynyz is also approved as a monotherapy for the first-line treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S., EU, Canada, and Switzerland, providing Incyte with broader market opportunities and enhancing its competitive position in oncology.
- Stock Price Dynamics: Incyte's stock closed at $95.94 on March 6, down $1.39 (1.43%), and slipped further to $95.40 in after-hours trading, indicating a cautious market reaction to the news.
See More
FDA Rejects Zynyz's Additional Indication Application
- FDA Rejection: The U.S. FDA has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte and MacroGenics, primarily due to compliance issues at a third-party manufacturing site operated by Novo Nordisk's Catalent unit, highlighting the stringent regulatory environment for drug approvals.
- Complete Response Letter: Incyte noted in its regulatory filing that the FDA issued a Complete Response Letter, citing Catalent Indiana's compliance as the sole approvability issue, which indicates that other aspects were not questioned, potentially providing hope for future applications.
- Clinical Trial Support: The supplemental Biologics License Application (sBLA) was supported by data from the company's Phase 3 POD1UM-304 trial, aiming to provide a combination therapy of antibody treatment and chemotherapy for adults with metastatic non-small cell lung cancer, showcasing the drug's potential market value.
- EU Approval Progress: Despite the FDA's rejection of the new indication application, Incyte simultaneously announced that Zynyz has received EU approval as a first-line treatment option for adults with SCAC, indicating that the drug still holds growth potential in international markets.
See More
Knight Therapeutics Submits MINJUVI Supplemental Application for New Indication
- New Indication Application: Knight Therapeutics' Argentine and Mexican affiliates have submitted a supplemental application for MINJUVI® (tafasitamab) to local regulatory agencies, aiming to expand the product's applicability in the Latin American market and enhance its competitive edge.
- Market Expansion Strategy: Since signing an exclusive supply agreement with Incyte in 2021, Knight has launched MINJUVI® in Brazil, Mexico, and Argentina, planning to leverage the new indication approval to meet diverse patient needs, thereby increasing sales potential and market share.
- Clinical Data Support: In a Phase 3 clinical trial for relapsed follicular lymphoma, MINJUVI® demonstrated a significant improvement in progression-free survival, reaching 22.37 months, indicating the drug's efficacy in treatment, which may attract more physician interest.
- Future Development Outlook: Knight Therapeutics CEO Samira Sakhia emphasized that MINJUVI® represents multiple therapies rather than a single product, and with the launch of new indications, the company will continue to focus on improving patient health and driving long-term growth in the Latin American market.
See More
Knight Therapeutics Secures New Drug Approval in Brazil
- New Indication Approved: Knight Therapeutics' Brazilian affiliate, United Medical Ltda., received ANVISA approval for MINJUVI® in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, marking a significant expansion in treatment options that is expected to greatly improve patient outcomes.
- Clinical Data Support: The approval is backed by clinical study data demonstrating meaningful response rates and durable disease control with MINJUVI® combined with R2, which is anticipated to enhance Knight's competitiveness in the Latin American market and meet the growing treatment demand.
- Strengthened Strategic Partnership: Knight entered into an exclusive supply and distribution agreement with Incyte in 2021, further solidifying its position in the Latin American market, with expectations that the promotion of MINJUVI® will increase market share and enhance the company's influence in oncology treatment.
- Positive Future Outlook: This approval not only provides Brazilian patients with a new treatment option but also showcases Knight's strong capabilities in rapid approval processes, which is expected to drive business growth in Latin America and further fulfill its commitment to high-quality cancer care.
See More
Companies Like Monster, Palantir, and Expedia That Can Withstand Market Turbulence
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Volatility on Wall Street: The market remains volatile, prompting equity strategists to seek out resilient stocks that can withstand the current economic pressures.
See More
Stocks Like Monster Beverage and Expedia Poised to Endure Market Fluctuations with Higher Profit Margins.
Market Impact: The stock market experienced a decline due to the ongoing war in the Middle East, which led to a rise in oil prices.
Strategic Response: Equity strategists at CIBC Capital Markets are identifying stocks that may remain resilient in the current volatile market conditions.
See More
Incyte Receives EU Approval for Zynyz in New Indication
- New Indication Approval: Incyte announced that its drug Zynyz (retifanlimab) in combination with carboplatin and paclitaxel has received approval from the European Commission for the treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC), marking the second indication for the drug in Europe.
- Clinical Trial Support: This approval is supported by data from the Phase 3 POD1UM-303/InterAACT2 trial, which evaluated the efficacy of Zynyz versus placebo in combination with carboplatin and paclitaxel, demonstrating significant effectiveness in adult patients who had not previously received systemic chemotherapy.
- Market Potential Expansion: Zynyz is also approved as a monotherapy for the first-line treatment of metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S., EU, Canada, and Switzerland, providing Incyte with broader market opportunities and enhancing its competitive position in oncology.
- Stock Price Dynamics: Incyte's stock closed at $95.94 on March 6, down $1.39 (1.43%), and slipped further to $95.40 in after-hours trading, indicating a cautious market reaction to the news.
See More
FDA Rejects Zynyz's Additional Indication Application
- FDA Rejection: The U.S. FDA has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte and MacroGenics, primarily due to compliance issues at a third-party manufacturing site operated by Novo Nordisk's Catalent unit, highlighting the stringent regulatory environment for drug approvals.
- Complete Response Letter: Incyte noted in its regulatory filing that the FDA issued a Complete Response Letter, citing Catalent Indiana's compliance as the sole approvability issue, which indicates that other aspects were not questioned, potentially providing hope for future applications.
- Clinical Trial Support: The supplemental Biologics License Application (sBLA) was supported by data from the company's Phase 3 POD1UM-304 trial, aiming to provide a combination therapy of antibody treatment and chemotherapy for adults with metastatic non-small cell lung cancer, showcasing the drug's potential market value.
- EU Approval Progress: Despite the FDA's rejection of the new indication application, Incyte simultaneously announced that Zynyz has received EU approval as a first-line treatment option for adults with SCAC, indicating that the drug still holds growth potential in international markets.
See More
